Biomedicines (May 2022)

Identification of LOC101927355 as a Novel Biomarker for Preeclampsia

  • Reyna Peñailillo,
  • Lara J. Monteiro,
  • Stephanie Acuña-Gallardo,
  • Felipe García,
  • Victoria Velásquez,
  • Paula Correa,
  • Pilar Díaz,
  • Patricia P. Valdebenito,
  • Cristina Navarro,
  • Roberto Romero,
  • Mario Sánchez,
  • Sebastián E. Illanes,
  • Gino Nardocci

DOI
https://doi.org/10.3390/biomedicines10061253
Journal volume & issue
Vol. 10, no. 6
p. 1253

Abstract

Read online

Preeclampsia, a disorder with a heterogeneous physiopathology, can be attributed to maternal, fetal, and/or placental factors. Long non-coding RNAs (lncRNAs) refer to a class of non-coding RNAs, the essential regulators of biological processes; their differential expression has been associated with the pathogenesis of multiple diseases. The study aimed to identify lncRNAs, expressed in the placentas and plasma of patients who presented with preeclampsia, as potential putative biomarkers of the disease. In silico analysis was performed to determine lncRNAs differentially expressed in the placentas of patients with preeclampsia, using a previously published RNA-Seq dataset. Seven placentas and maternal plasma samples collected at delivery from preterm preeclamptic patients (≤37 gestational weeks of gestation), and controls were used to validate the expression of lncRNAs by qRT-PCR. Six lncRNAs were validated and differentially expressed (p p = 0.03) in preeclamptic patients compared to the control group. In silico analyses showed the cytoplasmic location of LOC101927355, which suggests a role in post-transcriptional gene regulation. The detection of LOC101927355 in the placenta and plasma opens new possibilities for understanding the pathogenesis of preeclampsia and for its potential use as a biomarker.

Keywords